Related Experiment Videos
Effects of catecholamine application to brain-dead donors on graft survival in solid organ transplantation
P Schnuelle1, S Berger, J de Boer
1University Hospital Mannheim, Theodor Kutzer Ufer 1-3, 68167 Mannheim, Germany. schnuell@rumms.uni-mannheim.de
Insights
Donor use of catecholamines improved kidney transplant survival, showing a dose-dependent benefit comparable to HLA matching. However, norepinephrine use predicted heart transplant nonfunction, though liver grafts were unaffected.
Area of Science:
- Transplantation immunology
- Organ donor management
- Pharmacology
Background:
- Previous single-center studies suggested donor catecholamine use reduces kidney allograft rejection.
- This study expands on these findings by examining adrenergic agent effects on graft survival across multiple transplant types.
Purpose of the Study:
- To investigate the impact of donor administration of adrenergic agents on graft survival in kidney, liver, and heart transplants.
- To determine if catecholamine use in organ donors affects short-term and long-term graft outcomes.
Main Methods:
- Analysis of 4190 transplants (2415 kidney, 755 liver, 720 heart) from the Eurotransplant registry (1993).
- Systematic review of 1742 donor record forms for adrenergic agent use, categorized as none, single, or combined.
- Multivariate Cox regression analysis adjusted for key donor and recipient factors.
Main Results:
- Donor catecholamine use was linked to improved 4-year kidney graft survival (HR 0.85), with a dose-dependent effect.
- The benefit of catecholamines in kidney transplantation was comparable to prospective HLA matching.
- Norepinephrine use predicted initial nonfunction in heart transplants (HR 1.66) but not liver grafts.
Conclusions:
- Optimizing brain-dead organ donor management, including selective adrenergic agent use, can enhance graft survival.
- Adrenergic agents may offer benefits without adverse recipient effects, warranting further research into optimal drug selection, dosage, and duration.
Background:
In a recent single-center study, donor use of catecholamines was identified to reduce kidney allograft rejection. This study investigates the effects of donor employment of adrenergic agents on graft survival in a large data base, including liver and heart transplants.
Methods:
The study was based on the registry of the Eurotransplant International Foundation including 2415 kidney, 755 liver, and 720 heart transplants performed between January 1 and December 31, 1993. A total of 1742 donor record forms referring to the cadaveric donor activities in 1993 were systematically reviewed with regard to employment of adrenergic agents. Catecholamine use was simply coded dichotomously and divided into three strata according to zero, single, and combined application. Multivariate Cox regression including age, gender, cause of brain death, cold ischemia, HLA-mismatching, number of previous transplants, and urgency in liver transplants was applied for statistical analysis.
Results:
Donor employment of catecholamines was associated with increased 4-year graft survival after kidney transplantation (hazard ratio [HR], 0.85; 95% confidence interval [95% CI], 0.74-0.98). The benefit is conferred in a dose-dependent manner and compares in quantitative terms with prospective HLA matching on class I and class II antigens (HR, 0.90; 95% CI, 0.84-0.97). Use of norepinephrine was predictive of initial nonfunction after heart transplantation (HR, 1.66; 95% CI, 1.14-2.43), but did not compromise liver grafts (HR, 0.94; 95% CI, 0.67-1.32).
Conclusions:
Optimizing the management of brain-dead organ donors, including the possibility of selective administration of adrenergic agents, may provide a major benefit on graft survival without adverse side effects for the recipients. Further investigation on best use of adrenergic drugs, optimum dosage, and duration is warranted.